Omeros (NASDAQ: OMER) experienced a nearly 76% surge in its stock price after receiving FDA approval for its Yartemlea drug, the first FDA-approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).

Yartemlea showed a 73% 100-day survival rate in clinical trials for TA-TMA patients, leading to FDA approval. Omeros is preparing for a January launch, establishing billing codes and a patient support program for the medication.

CEO Gregory Demopulos expressed excitement over the approval, calling it a significant milestone. Omeros now holds a dominant position in the market with a diverse pipeline, positioning the company for success with other treatments.

The Motley Fool Stock Advisor team did not include Omeros in their list of top 10 stocks to buy now, but highlighted its potential for substantial returns. Stock Advisor has historically outperformed the S&P 500 with a total average return of 985%.

*Stock Advisor returns as of December 22, 2025. Eric Volkman and The Motley Fool have no positions in the mentioned stocks or companies. “Why Omeros Stock Skyrocketed Today” was originally published by The Motley Fool.

Read more at Yahoo Finance: Why Omeros Stock Skyrocketed Today